KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a ...
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in ...
Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s ...
Clinical Trials Arena on MSN
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
The BEHOLD-1 trial is evaluating the Mo-Rez injection's tolerability, safety and efficacy.
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...
A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of ...
SynOx Therapeutics completed enrollment for the phase 3 TANGENT study of emactuzumab for tenosynovial giant cell tumors, with results expected in 2026. ALX Oncology launched a phase 1 trial of ALX2004 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results